151 related articles for article (PubMed ID: 29514235)
21. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.
Uthman OA; Okwundu C; Gbenga K; Volmink J; Dowdy D; Zumla A; Nachega JB
Ann Intern Med; 2015 Jul; 163(1):32-9. PubMed ID: 26148280
[TBL] [Abstract][Full Text] [Related]
22. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
Walker AS; Ford D; Gilks CF; Munderi P; Ssali F; Reid A; Katabira E; Grosskurth H; Mugyenyi P; Hakim J; Darbyshire JH; Gibb DM; Babiker AG
Lancet; 2010 Apr; 375(9722):1278-86. PubMed ID: 20347483
[TBL] [Abstract][Full Text] [Related]
23. Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium.
Desmonde S; Neilan AM; Musick B; Patten G; Chokephaibulkit K; Edmonds A; Duda SN; Malateste K; Wools-Kaloustian K; Ciaranello AL; Davies MA; Leroy V;
J Int AIDS Soc; 2020 Oct; 23(10):e25617. PubMed ID: 33034417
[TBL] [Abstract][Full Text] [Related]
24. Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study.
Gupta-Wright A; Corbett EL; Wilson D; van Oosterhout JJ; Dheda K; Huerga H; Peter J; Bonnet M; Alufandika-Moyo M; Grint D; Lawn SD; Fielding K
PLoS Med; 2019 Apr; 16(4):e1002776. PubMed ID: 30951533
[TBL] [Abstract][Full Text] [Related]
25. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
Smitson CC; Tenna A; Tsegaye M; Alemu AS; Fekade D; Aseffa A; Blumberg HM; Kempker RR
PLoS One; 2014; 9(1):e85698. PubMed ID: 24465651
[TBL] [Abstract][Full Text] [Related]
26. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
27. Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling Analysis.
Schomaker M; Davies MA; Malateste K; Renner L; Sawry S; N'Gbeche S; Technau KG; Eboua F; Tanser F; Sygnaté-Sy H; Phiri S; Amorissani-Folquet M; Cox V; Koueta F; Chimbete C; Lawson-Evi A; Giddy J; Amani-Bosse C; Wood R; Egger M; Leroy V;
Epidemiology; 2016 Mar; 27(2):237-46. PubMed ID: 26479876
[TBL] [Abstract][Full Text] [Related]
28. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.
Siedner MJ; Ng CK; Bassett IV; Katz IT; Bangsberg DR; Tsai AC
Clin Infect Dis; 2015 Apr; 60(7):1120-7. PubMed ID: 25516189
[TBL] [Abstract][Full Text] [Related]
29. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.
Kiertiburanakul S; Boettiger D; Lee MP; Omar SF; Tanuma J; Ng OT; Durier N; Phanuphak P; Ditangco R; Chaiwarith R; Kantipong P; Lee CK; Mustafa M; Saphonn V; Ratanasuwan W; Merati TP; Kumarasamy N; Wong WW; Zhang F; Pham TT; Pujari S; Choi JY; Yunihastuti E; Sungkanuparph S; ;
J Int AIDS Soc; 2014; 17(1):18804. PubMed ID: 24598459
[TBL] [Abstract][Full Text] [Related]
30. High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites.
Ousley J; Niyibizi AA; Wanjala S; Vandenbulcke A; Kirubi B; Omwoyo W; Price J; Salumu L; Szumilin E; Spiers S; van Cutsem G; Mashako M; Mangana F; Moudarichirou R; Harrison R; Kalwangila T; Lumowo G; Lambert V; Maman D
Clin Infect Dis; 2018 Mar; 66(suppl_2):S126-S131. PubMed ID: 29514239
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
; Keiser O; Anastos K; Schechter M; Balestre E; Myer L; Boulle A; Bangsberg D; Touré H; Braitstein P; Sprinz E; Nash D; Hosseinipour M; Dabis F; May M; Brinkhof MW; Egger M
Trop Med Int Health; 2008 Jul; 13(7):870-9. PubMed ID: 18373510
[TBL] [Abstract][Full Text] [Related]
32. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
Stringer JS; Zulu I; Levy J; Stringer EM; Mwango A; Chi BH; Mtonga V; Reid S; Cantrell RA; Bulterys M; Saag MS; Marlink RG; Mwinga A; Ellerbrock TV; Sinkala M
JAMA; 2006 Aug; 296(7):782-93. PubMed ID: 16905784
[TBL] [Abstract][Full Text] [Related]
33. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.
Carriquiry G; Fink V; Koethe JR; Giganti MJ; Jayathilake K; Blevins M; Cahn P; Grinsztejn B; Wolff M; Pape JW; Padgett D; Madero JS; Gotuzzo E; McGowan CC; Shepherd BE
J Int AIDS Soc; 2015; 18(1):20016. PubMed ID: 26165322
[TBL] [Abstract][Full Text] [Related]
34. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.
DART Trial Team
AIDS; 2008 Jan; 22(2):237-47. PubMed ID: 18097226
[TBL] [Abstract][Full Text] [Related]
35. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.
Nash D; Katyal M; Brinkhof MW; Keiser O; May M; Hughes R; Dabis F; Wood R; Sprinz E; Schechter M; Egger M;
AIDS; 2008 Nov; 22(17):2291-302. PubMed ID: 18981768
[TBL] [Abstract][Full Text] [Related]
36. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
Lawn SD; Myer L; Bekker LG; Wood R
AIDS; 2007 Jan; 21(3):335-41. PubMed ID: 17255740
[TBL] [Abstract][Full Text] [Related]
37. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
Gabillard D; Lewden C; Ndoye I; Moh R; Segeral O; Tonwe-Gold B; Etard JF; Pagnaroat M; Fournier-Nicolle I; Eholié S; Konate I; Minga A; Mpoudi-Ngole E; Koulla-Shiro S; Zannou DM; Anglaret X; Laurent C;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):555-61. PubMed ID: 23274931
[TBL] [Abstract][Full Text] [Related]
38. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
[TBL] [Abstract][Full Text] [Related]
39. Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa.
Zanoni BC; Phungula T; Zanoni HM; France H; Feeney ME
PLoS One; 2011; 6(7):e22706. PubMed ID: 21829487
[TBL] [Abstract][Full Text] [Related]
40. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.
Clouse K; Pettifor A; Maskew M; Bassett J; Van Rie A; Gay C; Behets F; Sanne I; Fox MP
AIDS; 2013 Feb; 27(4):645-50. PubMed ID: 23169326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
